Ivan S. Abramov

Mr. Ivan S. Abramov

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2018 in BMC Genomics
Verified
Journal Article
Open access
PDF file
Elena A. PudovaElena A. Pudova
Elena A. Pudova
AKAnna Kudryavtseva
Anna Kudryavtseva
MFMaria S. Fedorova
Maria S. Fedorova
AZAndrew R. Zaretsky
Andrew R. Zaretsky
DSDmitry S. Shcherbo
Dmitry S. Shcherbo
Anastasiya SnezhkinaAnastasiya Snezhkina
Anastasiya Snezhkina
Colorectal cancer (CRC) is a common cancer worldwide. The main cause of death in CRC includes tumor progression and metastasis. At molecular level, these processes may be triggered by epithelial-mesenchymal transition (EMT) and necessitates specific alterations in cell metabolism. Although several EMT-related metabolic changes have been described in CRC, the mechanism is still poorly understood. Using CrossHub software, we analyzed RNA-Seq expression profile data of CRC derived from The Cancer Genome Atlas (TCGA) project. Correlation analysis between the change in the expression of genes involved in glycolysis and EMT was performed. We obtained the set of genes with significant correlation coefficients, which included 21 EMT-related genes and a single glycolytic gene, HK3. The mRNA level of these genes was measured in 78 paired colorectal cancer samples by quantitative polymerase chain reaction (qPCR). Upregulation of HK3 and deregulation of 11 genes (COL1A1, TWIST1, NFATC1, GLIPR2, SFPR1, FLNA, GREM1, SFRP2, ZEB2, SPP1, and RARRES1) involved in EMT were found. The results of correlation study showed that the expression of HK3 demonstrated a strong correlation with 7 of the 21 examined genes (ZEB2, GREM1, TGFB3, TGFB1, SNAI2, TWIST1, and COL1A1) in CRC. Upregulation of HK3 is associated with EMT in CRC and may be a crucial metabolic adaptation for rapid proliferation, survival, and metastases of CRC cells.

14 February 2020 in Viruses
Verified
Journal Article
Open access
PDF file
Daniil KiselevDaniil Kiselev
Daniil Kiselev
AMAlina Matsvay
Alina Matsvay
IAIvan S. Abramov
Ivan S. Abramov
VDVladimir George Dedkov
Vladimir George Dedkov
GSGerman Shipulin
German Shipulin
Kamil F KhafizovKamil F Khafizov
Kamil F Khafizov
Viruses are evolving at an alarming rate, spreading and inconspicuously adapting to cutting-edge therapies. Therefore, the search for rapid, informative and reliable diagnostic methods is becoming urgent as ever. Conventional clinical tests (PCR, serology, etc.) are being continually optimized, yet provide very limited data. Could high throughput sequencing (HTS) become the future gold standard in molecular diagnostics of viral infections? Compared to conventional clinical tests, HTS is universal and more precise at profiling pathogens. Nevertheless, it has not yet been widely accepted as a diagnostic tool, owing primarily to its high cost and the complexity of sample preparation and data analysis. Those obstacles must be tackled to integrate HTS into daily clinical practice. For this, three objectives are to be achieved: (1) designing and assessing universal protocols for library preparation, (2) assembling purpose-specific pipelines, and (3) building computational infrastructure to suit the needs and financial abilities of modern healthcare centers. Data harvested with HTS could not only augment diagnostics and help to choose the correct therapy, but also facilitate research in epidemiology, genetics and virology. This information, in turn, could significantly aid clinicians in battling viral infections.

1 May 2013 in Dyes and Pigments
Verified
Journal Article
Closed access
VSValeriy E. Shershov
Valeriy E. Shershov
MSMaksim A. Spitsyn
Maksim A. Spitsyn
VKViktoriya E. Kuznetsova
Viktoriya E. Kuznetsova
ETEdward N. Timofeev
Edward N. Timofeev
OIOlga A. Ivashkina
Olga A. Ivashkina
ACAlexander V. Chudinov
Alexander V. Chudinov

13 February 2018 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
Anastasiya SnezhkinaAnastasiya Snezhkina
Anastasiya Snezhkina
ELElena N. Lukyanova
Elena N. Lukyanova
Dmitry V KalininDmitry V Kalinin
Dmitry V Kalinin
APAnatoly V. Pokrovsky
Anatoly V. Pokrovsky
Alexey DmitrievAlexey Dmitriev
Alexey Dmitriev
AKAnna Kudryavtseva
Anna Kudryavtseva
Carotid body tumor (CBT) is a form of head and neck paragangliomas (HNPGLs) arising at the bifurcation of carotid arteries. Paragangliomas are commonly associated with germline and somatic mutations involving at least one of more than thirty causative genes. However, the specific functionality of a number of these genes involved in the formation of paragangliomas has not yet been fully investigated. Exome library preparation was carried out using Nextera® Rapid Capture Exome Kit (Illumina, USA). Sequencing was performed on NextSeq 500 System (Illumina). Exome analysis of 52 CBTs revealed potential driver mutations (PDMs) in 21 genes: ARNT, BAP1, BRAF, BRCA1, BRCA2, CDKN2A, CSDE1, FGFR3, IDH1, KIF1B, KMT2D, MEN1, RET, SDHA, SDHB, SDHC, SDHD, SETD2, TP53BP1, TP53BP2, and TP53I13. In many samples, more than one PDM was identified. There are also 41% of samples in which we did not identify any PDM; in these cases, the formation of CBT was probably caused by the cumulative effect of several not highly pathogenic mutations. Estimation of average mutation load demonstrated 6–8 mutations per megabase (Mb). Genes with the highest mutation rate were identified. Exome analysis of 52 CBTs for the first time revealed the average mutation load for these tumors and also identified potential driver mutations as well as their frequencies and co-occurrence with the other PDMs.

19 February 2019 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
TBTatiana S. Belysheva
Tatiana S. Belysheva
YVYana V. Vishnevskaya
Yana V. Vishnevskaya
TNTatiana Nasedkina
Tatiana Nasedkina
MEMarina Emelyanova
Marina Emelyanova
IAIvan S. Abramov
Ivan S. Abramov
MAMamed D. Aliev
Mamed D. Aliev
A giant congenital melanocytic nevus (GCMN) is found in 0.1% of live-born infants. If present, the lesion has a chance of about 6% to develop into malignant melanoma. Both children and adults can be affected by malignant melanoma arising in a giant congenital nevus. Up to 95% of GCMNs harbor NRAS mutations, and mutations in the BRAF, MC1R, TP53, and GNAQ genes have also been described. The individualization of therapy is required, but diagnostic and prognostic criteria remain controversial. We report two cases: 1) melanoma arising in a giant congenital nevus during the first month of life complicated with neurocutaneous melanosis (NCM), and 2) melanoma arising in a giant congenital nevus during the first 6 months of life. Pathology, immunohistochemistry, and genetic analyses of tumor tissue were performed. The first case revealed only a non-pathogenic P72R polymorphism of the TP53 gene in the homozygote condition. For the second case, a Q61K mutation was detected in the NRAS gene. Malignant melanoma associated with GCMN is rare and therefore poorly understood. Outcomes have been linked to the stage at diagnosis, but no additional pathological prognostic factors have been identified. The most frequent genetic event in giant CMNs is NRAS mutations, which was discovered in one of our cases. To accumulate evidence to improve disease prognosis and outcomes, children with congenital melanocytic nevus should be included in a systemic follow-up study from birth.

28 December 2017 in BMC Genomic Data
Verified
Journal Article
Open access
PDF file
MFMaria S. Fedorova
Maria S. Fedorova
Anastasiya SnezhkinaAnastasiya Snezhkina
Anastasiya Snezhkina
Elena A. PudovaElena A. Pudova
Elena A. Pudova
IAIvan S. Abramov
Ivan S. Abramov
ALAnastasiya V. Lipatova
Anastasiya V. Lipatova
AKAnna Kudryavtseva
Anna Kudryavtseva
Neuropilin and tolloid-like 2 (NETO2) is a single-pass transmembrane protein that has been shown primarily implicated in neuron-specific processes. Upregulation of NETO2 gene was also detected in several cancer types. In colorectal cancer (CRC), it was associated with tumor progression, invasion, and metastasis, and seems to be involved in epithelial-mesenchymal transition (EMT). However, the mechanism of NETO2 action is still poorly understood. We have revealed significant increase in the expression of NETO2 gene and deregulation of eight EMT-related genes in CRC. Four of them were upregulated (TWIST1, SNAIL1, LEF1, and FOXA2); the mRNA levels of other genes (FOXA1, BMP2, BMP5, and SMAD7) were decreased. Expression of NETO2 gene was weakly correlated with that of genes involved in the EMT process. We found considerable NETO2 upregulation, but no significant correlation between the expression of NETO2 and EMT-related genes in CRC. Thus, NETO2 may be involved in CRC progression, but is not directly associated with EMT.